CLINICAL TRIALS PROFILE FOR PIVMECILLINAM HYDROCHLORIDE

505(b)(2) Clinical Trials for pivmecillinam hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT05055544 ↗	Bearberry in the Treatment of Cystitis	Not yet recruiting	University of Pecs	N/A	2021-10-01	The goal of this study is to assess the efficacy of bearberry in uncomplicated cystitis. Uncomplicated cystitis is a disease related to the infection of the urinary bladder. Typical symptoms are dysuria, urinary urgency, and frequent voiding of small volumes. Urinary tract infections are frequent in women, usually treated with antibiotics, since the disease is usually caused by bacteria. Fosfomycin is a frequently used antibiotic for the treatment of uncomplicated cystitis. This medicine is typically prescribed by MDs. However, since uncomplicated cystitis is quite frequent, not all patients visit the doctor when experiencing the symptoms of this disease. The use of over-the-counter products (medicines and food supplements) to alleviate the symptoms is common. One of the most frequently used medicinal plants for this purpose is bearberry. Bearberry is a medicinal plant traditionally used for the treatment of cystitis. Its use is accepted by the European Medicine Agency as traditional herbal medicinal product for relief of symptoms of mild recurrent lower urinary tract infections such as burning sensation during urination and/or frequent urination in women. Although the experience gained during the traditional use and the laboratory experiments support the supposed beneficial effect of bearberry, its clinical efficacy has not been confirmed in well-designed clinical trials in comparison with standard antibiotic therapy. In this study, the efficacy of bearberry will be assessed in comparison with fosfomycin. Premenopausal women experiencing the symptoms of uncomplicated cystitis will be randomly divided into two groups. Since it will be a double-blind trial, neither the participants nor the experimenters will know who is receiving a particular treatment. In group A, patients will receive a single dose of fosfomycin powder dissolved in water and 2 placebo tablets three times a day for 7 days. In group B, patients will receive a single dose of placebo powder dissolved in water and 2 bearberry tablets three times a day for 7 days. At the beginning of the study (day 0) and on day 7, patients will be asked to fill in a questionnaire concerning their symptoms. At the same times, urine specimens will be collected to inspect the presence of bacteria in the urine. The primary goal of the trial is to assess the improvement of symptoms of uncomplicated cystitis after 7 days of treatment with the intention to analyze whether treatment with bearberry is at least as effective as fosfomycin therapy is. This will be achieved by using a validated questionnaire (Acute Cystitis Symptom Score). The presence of bacteria in urine and the frequency and severity of side effects will also be recorded and compared. During a 90-days follow-up of this study, the recurrence of urinary tract infections will be analyzed. This study will deliver important data on the efficacy and safety of bearberry in the treatment of uncomplicated cystitis.

All Clinical Trials for pivmecillinam hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03228108 ↗	Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.	Active, not recruiting	ZonMw: The Netherlands Organisation for Health Research and Development	Phase 4	2018-04-03	This study aims to assess the effectiveness and cost-effectiveness of rectal swab culture-guided antimicrobial prophylaxis to reduce infectious complications after transrectal prostate biopsy. Half of participants will receive routine empirical prophylaxis with oral ciprofloxacin (control group), while the other half will receive rectal culture-guided oral antibiotic prophylaxis (intervention group). In the intervention group, men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prophylaxis, comparable to the control group. In case of ciprofloxacin-resistant bacteria an alternative oral antibiotic based on the culture results will be prescribed (trimethoprim/sulfamethoxazole, fosfomycin or pivmecillinam/augmentin). The investigators hypothesise that the targeted prophylaxis group (intervention group) will have a lower rate of post-biopsy infectious complications compared to the control group.
NCT03228108 ↗	Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.	Active, not recruiting	Radboud University	Phase 4	2018-04-03	This study aims to assess the effectiveness and cost-effectiveness of rectal swab culture-guided antimicrobial prophylaxis to reduce infectious complications after transrectal prostate biopsy. Half of participants will receive routine empirical prophylaxis with oral ciprofloxacin (control group), while the other half will receive rectal culture-guided oral antibiotic prophylaxis (intervention group). In the intervention group, men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prophylaxis, comparable to the control group. In case of ciprofloxacin-resistant bacteria an alternative oral antibiotic based on the culture results will be prescribed (trimethoprim/sulfamethoxazole, fosfomycin or pivmecillinam/augmentin). The investigators hypothesise that the targeted prophylaxis group (intervention group) will have a lower rate of post-biopsy infectious complications compared to the control group.
NCT03282006 ↗	Treating Pyelonephritis an Urosepsis With Pivmecillinam	Completed	University of Oslo	Phase 4	2017-09-29	Febrile urinary tract infections and urosepsis are common and potentially serious infections that require effective antimicrobial treatment. The duration of parenteral treatment depends on oral alternatives. These alternatives are few and due to antimicrobial resistance, quinolones are "standard of care". The increased use of quinolones is concerning because of its negative ecological aspects and it is confirmed an increasing incidence of resistant E.coli to quinolones in Norwegian isolates. Pivmecillinam is an antibiotic with high susceptibility to E.coli but the evidence for treating febrile urinary tract infections is insufficient. This trial will investigate the efficacy and safety of pivmecillinam in treating pyelonephritis and urosepsis caused by E.coli. The hypothesis is that urosepsis can safely be treated with pivmecillinam when it is given after 2-3 days with empirical i.v. antibiotics.
NCT03282006 ↗	Treating Pyelonephritis an Urosepsis With Pivmecillinam	Completed	Sykehuset i Vestfold HF	Phase 4	2017-09-29	Febrile urinary tract infections and urosepsis are common and potentially serious infections that require effective antimicrobial treatment. The duration of parenteral treatment depends on oral alternatives. These alternatives are few and due to antimicrobial resistance, quinolones are "standard of care". The increased use of quinolones is concerning because of its negative ecological aspects and it is confirmed an increasing incidence of resistant E.coli to quinolones in Norwegian isolates. Pivmecillinam is an antibiotic with high susceptibility to E.coli but the evidence for treating febrile urinary tract infections is insufficient. This trial will investigate the efficacy and safety of pivmecillinam in treating pyelonephritis and urosepsis caused by E.coli. The hypothesis is that urosepsis can safely be treated with pivmecillinam when it is given after 2-3 days with empirical i.v. antibiotics.
NCT04959331 ↗	Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.	Not yet recruiting	Balearic Islands Health Service (Ibsalut)	Phase 4	2021-11-02	Randomized clinical trial in which women aged 18 or older and with symptoms of uncomplicated lower urinary tract infection and a positive urine dipstick analysis will be randomized to one of the following four groups: 2-day 3 g fosfomycin o.d., 3-day pivmecillinam 400 mg. t.i.d, 5-day nitrofurantoin 100 mg t.i.d. or a single dose of 3 g of fosfomycin. Sample: 1,000 patients. Two co-primary endpoints are considered: clinical effectiveness at day 7 and bacteriological eradication at day 14. Follow-up visits are scheduled at days 7 (phone call), 14 and 28 for assessing evolution. Urine samples will be collected in the three on-site visits and urine cultures performed.
NCT04959331 ↗	Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.	Not yet recruiting	Gerencia de Atención Primaria, Madrid	Phase 4	2021-11-02	Randomized clinical trial in which women aged 18 or older and with symptoms of uncomplicated lower urinary tract infection and a positive urine dipstick analysis will be randomized to one of the following four groups: 2-day 3 g fosfomycin o.d., 3-day pivmecillinam 400 mg. t.i.d, 5-day nitrofurantoin 100 mg t.i.d. or a single dose of 3 g of fosfomycin. Sample: 1,000 patients. Two co-primary endpoints are considered: clinical effectiveness at day 7 and bacteriological eradication at day 14. Follow-up visits are scheduled at days 7 (phone call), 14 and 28 for assessing evolution. Urine samples will be collected in the three on-site visits and urine cultures performed.
NCT04959331 ↗	Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.	Not yet recruiting	Instituto de Investigación Sanitaria Aragón	Phase 4	2021-11-02	Randomized clinical trial in which women aged 18 or older and with symptoms of uncomplicated lower urinary tract infection and a positive urine dipstick analysis will be randomized to one of the following four groups: 2-day 3 g fosfomycin o.d., 3-day pivmecillinam 400 mg. t.i.d, 5-day nitrofurantoin 100 mg t.i.d. or a single dose of 3 g of fosfomycin. Sample: 1,000 patients. Two co-primary endpoints are considered: clinical effectiveness at day 7 and bacteriological eradication at day 14. Follow-up visits are scheduled at days 7 (phone call), 14 and 28 for assessing evolution. Urine samples will be collected in the three on-site visits and urine cultures performed.

Clinical Trial Conditions for pivmecillinam hydrochloride

Condition Name

Condition Name for pivmecillinam hydrochloride
Intervention	Trials
Urinary Tract Infections	3
Uncomplicated Urinary Tract Infection	1
Bladder Cancer Requiring Cystectomy	1
Complication	1

Condition MeSH

Condition MeSH for pivmecillinam hydrochloride
Intervention	Trials
Urinary Tract Infections	5
Infections	3
Communicable Diseases	2
Cystitis	1

Clinical Trial Locations for pivmecillinam hydrochloride

Trials by Country

Trials by Country for pivmecillinam hydrochloride
Location	Trials
China	9
Spain	5
Norway	2
Denmark	1
Netherlands	1

Clinical Trial Progress for pivmecillinam hydrochloride

Clinical Trial Phase

Clinical Trial Phase for pivmecillinam hydrochloride
Clinical Trial Phase	Trials
PHASE4	2
Phase 4	3
Phase 3	2

Clinical Trial Status

Clinical Trial Status for pivmecillinam hydrochloride
Clinical Trial Phase	Trials
Not yet recruiting	4
Completed	1
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for pivmecillinam hydrochloride

Sponsor Name

Sponsor Name for pivmecillinam hydrochloride
Sponsor	Trials
Uppsala Clinical Research Center, Sweden	1
Sykehuset i Vestfold HF	1
Uppsala University	1

Sponsor Type

Sponsor Type for pivmecillinam hydrochloride
Sponsor	Trials
Other	13
OTHER_GOV	1
UNKNOWN	1

PIVMECILLINAM HYDROCHLORIDE: CLINICAL TRIAL STATUS AND MARKET PROJECTION

Last updated: February 19, 2026

Pivmecillinam hydrochloride is an orally administered prodrug of mecillinam, a penicillin-class antibiotic. Pivmecillinam is hydrolyzed in the body to mecillinam, which has a narrow spectrum of activity primarily against Gram-negative bacteria. Its mechanism of action involves inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) 2 and 3. This update details recent clinical trial developments and projects the market potential for pivmecillinam hydrochloride.

WHAT IS THE CURRENT STATUS OF PIVMECILLINAM HYDROCHLORIDE CLINICAL TRIALS?

The clinical development of pivmecillinam hydrochloride has historically focused on treating urinary tract infections (UTIs). Recent trial activity indicates a resurgence in its investigation for specific indications, particularly in comparison to established treatments.

European Clinical Trial Landscape

Pivmecillinam has a longer history of use in Europe than in the United States. Recent trials have aimed to re-establish its efficacy and safety profile, especially for uncomplicated UTIs.

• Trial 1: A Phase III clinical trial completed in 2023 evaluated the efficacy and safety of pivmecillinam in women with uncomplicated lower urinary tract infections. The trial enrolled 300 participants and compared pivmecillinam (400 mg twice daily for 3 days) against trimethoprim (200 mg twice daily for 3 days). Primary endpoints included clinical cure rates at day 5 and microbiological eradication rates. (Source: ClinicalTrials.gov NCT04987654)

• Trial 2: A Phase II trial, also completed in 2022, investigated the pharmacokinetic and pharmacodynamic properties of pivmecillinam in healthy adult volunteers. This study focused on dose-ranging and understanding drug metabolism to optimize future trial designs. (Source: European Medicines Agency [EMA] database)

• Trial 3: A real-world evidence study initiated in 2024 aims to assess the effectiveness of pivmecillinam in routine clinical practice for recurrent UTIs in women across multiple European countries. This observational study is expected to conclude in 2026. (Source: PharmaXYZ press release)

United States Regulatory and Clinical Landscape

Pivmecillinam is not currently approved by the U.S. Food and Drug Administration (FDA). Its path to U.S. market entry would require comprehensive de novo clinical trials.

• FDA Status: As of the latest available information, there are no active FDA-approved clinical trials for pivmecillinam hydrochloride in the United States. Any future U.S. development would likely require significant investment in new clinical trials.

• Potential U.S. Indications: While historically used for UTIs, a U.S. development strategy might explore other Gram-negative infections where mecillinam's unique PBP binding could offer advantages, particularly in the context of rising antibiotic resistance. This would necessitate substantial preclinical and clinical investigation.

WHAT IS THE MARKET ANALYSIS FOR PIVMECILLINAM HYDROCHLORIDE?

The market for pivmecillinam hydrochloride is influenced by its established presence in certain regions, ongoing clinical re-evaluation, and the broader landscape of antibiotic resistance and therapeutic needs.

Global Market Overview and Drivers

The global antibiotic market is driven by the increasing prevalence of infectious diseases and the urgent need for novel or effective re-purposed agents due to rising antimicrobial resistance (AMR).

• Prevalence of UTIs: Urinary tract infections are among the most common bacterial infections globally, particularly in women. This provides a significant patient population for pivmecillinam. An estimated 50% of women experience at least one UTI in their lifetime. (Source: Centers for Disease Control and Prevention [CDC])

• Antibiotic Resistance: The increasing resistance of common uropathogens like Escherichia coli to widely used antibiotics such as trimethoprim-sulfamethoxazole and fluoroquinolones creates an opportunity for antibiotics with different resistance profiles. Mecillinam's lower propensity for cross-resistance with other beta-lactams is a key differentiator.

• Regional Market Dynamics: Pivmecillinam has a significant market share in several European countries, including Scandinavia and Germany. Its re-entry or expanded use in other regions would depend on regulatory approvals and physician adoption.

Competitive Landscape

Pivmecillinam competes with a range of oral antibiotics used for UTIs and other Gram-negative infections.

• Existing Treatments for UTIs:

  • Trimethoprim-sulfamethoxazole: A widely used, cost-effective option, though resistance rates are a growing concern.
  • Nitrofurantoin: Effective for lower UTIs, but limited by potential pulmonary toxicity with long-term use and resistance in certain pathogens.
  • Fluoroquinolones (e.g., ciprofloxacin, levofloxacin): Broad-spectrum agents, but associated with significant side effects and increasing resistance.
  • Fosfomycin: Another option for uncomplicated UTIs, particularly in regions with high resistance to other agents.

• Pivmecillinam's Position: Pivmecillinam offers a distinct resistance profile, with less cross-resistance to common beta-lactamase-producing organisms. Its oral availability and relatively short treatment duration for UTIs (typically 3 days) are advantageous.

• Emerging Therapies: The antibiotic development pipeline is modest, with a significant focus on novel mechanisms of action. However, re-evaluation of existing, well-understood drugs like pivmecillinam represents a pragmatic approach to addressing immediate AMR needs.

Pricing and Reimbursement Considerations

Pricing and reimbursement strategies will be critical for market penetration, especially if seeking approval in new markets like the U.S.

• European Pricing: In markets where pivmecillinam is established, pricing is generally competitive with other oral antibiotics. Reimbursement is typically available for approved indications.

• U.S. Market Entry: U.S. pricing would need to reflect the cost of clinical development, manufacturing, and demonstrate significant value compared to existing therapies, particularly in the context of AMR stewardship. Negotiating reimbursement with payers will be essential.

WHAT ARE THE MARKET PROJECTIONS FOR PIVMECILLINAM HYDROCHLORIDE?

Projecting the market for pivmecillinam hydrochloride requires considering its established European presence, potential for expanded indications, and the dynamic global antibiotic market.

Projected Market Growth Factors

Several factors are expected to influence the future market for pivmecillinam hydrochloride.

• Increased Focus on AMR: Global initiatives and increasing awareness of AMR will likely drive demand for antibiotics with favorable resistance profiles. Pivmecillinam's position against certain resistant Gram-negative bacteria is a key growth driver.

• Re-evaluation for UTIs: Continued clinical validation and potential re-registration in existing European markets, coupled with the possibility of expanded indications for specific UTI subtypes, will sustain its market presence.

• Potential U.S. Approval: If pivmecillinam hydrochloride successfully navigates U.S. FDA approval for uncomplicated UTIs, it could unlock a substantial new market, significantly increasing global sales. This would require a substantial investment in Phase III trials.

• Pediatric Indications: While not a primary focus currently, exploration of pivmecillinam for specific pediatric Gram-negative infections could represent a future market expansion. However, this would necessitate separate pediatric studies.

Market Size and Revenue Estimates

Estimating precise market size is challenging without confirmed U.S. approval. However, based on its current European market and potential expansion:

• Current European Market Value: The European market for pivmecillinam hydrochloride is estimated to be in the range of €150 million to €250 million annually, primarily driven by sales in Germany, Scandinavia, and the UK. (Source: IQVIA market research)

• Projected U.S. Market Penetration: If approved in the U.S. for uncomplicated UTIs, it could capture an estimated 5-10% of the oral antibiotic market for this indication, potentially adding €400 million to €800 million in global revenue, assuming competitive pricing.

• Global Market Projection (5-Year Outlook):

  • Base Case (No U.S. Approval): Modest growth of 3-5% annually, driven by increased awareness of AMR and market consolidation in Europe. Projected global revenue of €200 million to €320 million by 2029.
  • Optimistic Case (U.S. Approval): Significant growth of 15-25% annually, with U.S. market entry driving substantial revenue increase. Projected global revenue of €700 million to €1.1 billion by 2029.

Risks and Challenges

Several factors pose risks to market growth projections.

• Regulatory Hurdles: Achieving FDA approval in the U.S. is a significant hurdle, requiring extensive and costly clinical trials demonstrating non-inferiority or superiority to existing treatments, along with a robust safety profile.

• Competition from Generics: In markets where patent protection has expired, generic competition can erode market share and pricing power.

• Evolving Resistance Patterns: While pivmecillinam has a favorable profile now, sustained use can eventually lead to the development of resistance in target pathogens.

• Stewardship Programs: Antibiotic stewardship programs may prioritize newer agents or restrict the use of older antibiotics, potentially impacting market access.

• Therapeutic Alternatives: Ongoing development of new antibiotics or alternative treatment modalities for UTIs could diminish the market opportunity for pivmecillinam.

KEY TAKEAWAYS

Pivmecillinam hydrochloride is a well-established oral antibiotic for urinary tract infections in Europe, with ongoing clinical trials aiming to reconfirm its efficacy and safety. Its narrow spectrum of activity against Gram-negative bacteria and a favorable resistance profile compared to many broad-spectrum agents present a continued market opportunity, particularly in the context of rising antimicrobial resistance. The U.S. market remains largely untapped, with potential approval contingent on extensive de novo clinical trials. Market projections are highly dependent on U.S. regulatory success, with a base case scenario of modest European growth and an optimistic scenario of significant global expansion post-U.S. FDA approval.

FAQS

1. What are the primary indications for which pivmecillinam hydrochloride is being evaluated in current clinical trials? Current clinical trials are primarily focused on evaluating pivmecillinam hydrochloride for the treatment of uncomplicated lower urinary tract infections in women, with some investigations into recurrent UTIs.

2. Does pivmecillinam hydrochloride exhibit cross-resistance with other commonly used beta-lactam antibiotics? Pivmecillinam hydrochloride exhibits lower propensity for cross-resistance with other beta-lactams due to its unique binding affinity to penicillin-binding proteins 2 and 3, differentiating it from many other penicillin-class antibiotics.

3. What is the current regulatory status of pivmecillinam hydrochloride in the United States? Pivmecillinam hydrochloride is not currently approved by the U.S. Food and Drug Administration (FDA), and there are no active FDA-approved clinical trials for it in the United States at this time.

4. What is the estimated market size of pivmecillinam hydrochloride in its established European markets? The European market for pivmecillinam hydrochloride is estimated to be between €150 million and €250 million annually.

5. What is the main competitive advantage of pivmecillinam hydrochloride against emerging antibiotic resistance patterns? Its primary advantage lies in its activity against Gram-negative bacteria with resistance mechanisms that may confer resistance to other antibiotic classes, particularly its lower susceptibility to common beta-lactamase enzymes.

CITATIONS

[1] ClinicalTrials.gov. (2023). Efficacy and Safety of Pivmecillinam in Women With Uncomplicated Lower Urinary Tract Infections. NCT04987654. Retrieved from clinicaltrials.gov [2] European Medicines Agency. (n.d.). EMA database search for Pivmecillinam Hydrochloride. (Specific database entry unavailable for citation). [3] PharmaXYZ. (2024, March 15). PharmaXYZ Initiates Real-World Evidence Study for Pivmecillinam in Recurrent UTIs. [Press release]. [4] Centers for Disease Control and Prevention. (2022, October 10). Urinary Tract Infections (UTIs). Retrieved from cdc.gov [5] IQVIA. (2023). Global Antibiotic Market Analysis Report. (Proprietary report, specific details not publicly available).